Cohance Lifesciences Ltd.
COHANCEHealthcareR1 raw held document library
Coverage
| Dataset | On disk | Usable | State |
|---|---|---|---|
| Results XBRL (NSE + BSE) | 73 | 24 | 24 quarter-ends |
| Annual reports | 7 | 7 | identity graded |
| Earnings calls | 24 | 21 | transcripts and analyst meets only |
| Shareholding | 21 | 21 | |
| Related party | 5 | 5 | |
| Investor decks | 0 | 0 | cohort of 48 companies only |
Financial statements in parse — expected 19 Sep 2026. Nothing from the superseded legacy store is shown.
Earnings calls
17 transcript(s)/analyst meet(s) served; 3 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 17 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20220513 | 2022-03-31 | yes | |
| ANALYST_MEET | 20220608 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220816 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221115 | 2022-09-30 | yes | |
| TRANSCRIPT | 20221230 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230213 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230602 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230814 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231114 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240209 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240604 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240814 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241117 | 2024-09-30 | yes | |
| DUPLICATE | 20241117 | 2024-09-30 | no | |
| TRANSCRIPT | 20241213 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250218 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250602 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250819 | 2025-06-30 | yes | |
| DUPLICATE | 20250819 | 2025-06-30 | no | |
| TRANSCRIPT | 20251101 | 2025-09-30 | yes | |
| TRANSCRIPT | 20251117 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260515 | 2026-03-31 | yes | |
| DUPLICATE | 20260515 | 2026-03-31 | no | |
| TRANSCRIPT | 20260811 | 2026-06-30 | yes |